This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Study of Rubitecan in Cancer Patients With Renal or Hepatic Dysfunction

This study has been completed.
Information provided by (Responsible Party):
Astex Pharmaceuticals Identifier:
First received: June 3, 2005
Last updated: January 22, 2013
Last verified: June 2005
Cancer patients with liver or renal dysfunction will be treated with rubitecan capsules to define the maximum tolerated dose and the dose-limiting toxicity in this patient population, and to perform pharmacokinetic studies of rubitecan in this patient population.

Condition Intervention Phase
Tumors Drug: Rubitecan Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase I Study of Rubitecan (RFS 2000) in the Treatment of Cancer Patients With Organ Dysfunction

Further study details as provided by Astex Pharmaceuticals:

Estimated Enrollment: 54
Study Start Date: August 2001

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • The patient is at least 18 years of age.
  • The patient has histologically or cytologically proven malignancy recurrent or refractory to standard treatment or for which there is no standard therapy.
  • The patient has measurable disease.
  • The patient has sufficiently recovered from the acute toxic effects of previous chemotherapy, radiotherapy (no less than 3 weeks prior to randomization), and/or immunotherapy.
  • The patient's estimated life expectancy is at least 8 weeks.
  • The patient has a National Cancer Institute Common Toxicity Criteria (NCI CTC) Performance Status between 0 and 2.
  • The patient has adequate bone marrow function.
  • The patient must not have active central nervous system (CNS) metastases.

Exclusion Criteria:

  • The patient has any serious, uncontrolled intercurrent illness or infection.
  • The patient is receiving anti-retroviral therapy (HAART) for HIV infection.
  • The patient is pregnant or nursing.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00113113

United States, Missouri
Washington University School of Medicine
St. Louis, Missouri, United States, 63110
The Center for Cancer Care and Research
St. Louis, Missouri, United States, 63141
Sponsors and Collaborators
Astex Pharmaceuticals
  More Information

Responsible Party: Astex Pharmaceuticals Identifier: NCT00113113     History of Changes
Other Study ID Numbers: RFS 2000-40
RFS 2000-040
Study First Received: June 3, 2005
Last Updated: January 22, 2013

Keywords provided by Astex Pharmaceuticals:
solid tumors
organ dysfunction
renal dysfunction
hepatic dysfunction
RFS 2000

Additional relevant MeSH terms:
Antineoplastic Agents
Topoisomerase I Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents, Phytogenic processed this record on August 18, 2017